Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 3 , Pages 190-201 , September 2006

Influence of formulation factors on methyl-ALA-induced protoporphyrin IX accumulation in vivo

  • Ryan F. Donnelly, PhD

      Affiliations

    • School of Pharmacy, Queens University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello 0310, Oslo, Norway
    • Corresponding Author InformationCorresponding author. Tel.: +44 2890 972 251; fax: +44 2890 247 794.
    • ,
  • Petras Juzenas

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello 0310, Oslo, Norway
    • Fellow of the Norwegian Cancer Society, P.O. Box 4 Sentrum 0101, Oslo, Norway
    • ,
  • Paul A. McCarron

      Affiliations

    • School of Pharmacy, Queens University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
    • ,
  • Li-Wei Ma

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello 0310, Oslo, Norway
    • ,
  • A. David Woolfson

      Affiliations

    • School of Pharmacy, Queens University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
    • ,
  • Johan Moan

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello 0310, Oslo, Norway
    • Institute of Physics, University of Oslo, P.O. Box 1048 Blindern 0316, Oslo, Norway

References 

  1. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principals and present clinical experience. J Photochem Photobiol B: Biol. 1990;6:143–148
  2. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolevulinic acid for superficial primary and secondary cancer. Br J Cancer. 1994;69:605–608
  3. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical 5-aminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B: Biol. 1995;29:53–57
  4. Soler AM, Warloe T, Tausjo J, Berner A. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Dermatol Venereol. 1999;79:204–206
  5. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical 5-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol. 1994;130:743–751
  6. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol. 1996;135:766–771
  7. Morton CA, Whitehurst C, Moore JV, MacKie RM. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol. 2000;143:767–772
  8. Meijnders PJN, Star WM, De Bruijn RS, et al. Clinical results of photodynamic therapy for superficial skin malignancies or actinic keratosis using topical 5-aminolevulinic acid. Lasers Med Sci. 1996;11:123–131
  9. Jeffes EW, McCullough JL, Weinstein GP, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: a pilot dose-ranging study. Arch Dermatol. 1997;133:727–732
  10. Dijkstra AT, Majoie IML, van Dongen JWF, van Weelden H, van Vloten WA. Photodynamic therapy with violet light and topical 5-aminolevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. J Eur Acad Dermatol Venereol. 2001;15:550–554
  11. Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH. Photodynamic therapy for basal cell carcinoma: effect of tumour thickness and duration of photosensitiser application on response. Arch Dermatol. 1998;134:248–249
  12. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolevulinate-based photodynamic therapy alone with prior curettage. Br J Dermatol. 2001;145:467–471
  13. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: a report of a workshop of the British Photodermatology Group. Br J Dermatol. 2002;146:552–567
  14. Lopez RF, Lange N, Guy RH, Bentley MVLB. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev. 2004;56:77–94
  15. Donnelly RF, McCarron PA, Woolfson AD. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem Photobiol. 2005;81:750–767
  16. Fritsch C, Lang K, Neuse W, Ruzicka T, Lehmann P. Photodynamic diagnosis and therapy in dermatology. Skin Pharmacol Appl Skin Physiol. 1998;11:358–373
  17. Moan J, Van den Akker JTHM, Juzenas P, et al. On the basis for tumor selectivity in the 5-aminolevulinic acid-induced synthesis of protoporphyrin IX. J Porphyrins Phthalocyanines. 2001;5:170–176
  18. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol. 2001;137:319–324
  19. Markham T, Collins P. Topical 5-aminolevulinic acid photodynamic therapy for extensive scalp actinic keratoses. Br J Dermatol. 2001;145:502–504
  20. McCarron PA, Donnelly RF, Woolfson AD, Zawislak A. Photodynamic therapy of vulval intraepithelial neoplasia using bioadhesive patch-based delivery of aminolevulinic acid. Drug Deliv Syst Sci. 2003;3:59–64
  21. Zawislak A, McCarron PA, McCluggage WG, et al. Successful photodynamic therapy of vulval Paget's disease using a novel patch-based delivery system containing 5-aminolevulinic acid. Br J Obstet Gynaecol. 2004;111:1–3
  22. McCarron PA, Donnelly RF, Woolfson AD, Zawislak A, Price JH, Maxwell P. Photodynamic treatment of lichen sclerosus and squamous hyperplasia using sustained topical delivery of aminolevulinic acid from a novel bioadhesive. Br J Dermatol. 2004;151(Suppl. 68):105–106
  23. McCarron PA, Donnelly RF, Zawislak A, Woolfson AD, Price JH, McClelland R. Evaluation of a water-soluble bioadhesive patch for photodynamic therapy of vulval lesions. Int J Pharm. 2005;293:11–23
  24. Ahmadi S, McCarron PA, Donnelly RF, Woolfson AD, McKenna K. Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: a pilot study. Exp Dermatol. 2004;13:1–7
  25. McLoone N, Donnelly RF, McCarron PA, Walsh M, McKenna K. Aminolevulinic acid penetration into nodular basal cell carcinomas: Influence of different concentrations and application times on amounts of ALA delivered via a bioadhesive patch. Clin Photodyn. 2004;1:5–6
  26. McCarron PA, Woolfson AD, Donnelly RF, Andrews GP, Zawislak A, Price JH. Influence of plasticiser type and storage conditions on the properties of poly(methyl vinyl ether-co-maleic anhydride) bioadhesive films. J Appl Polym Sci. 2004;91:1576–1589
  27. Kaliszewski M, Kwasny M, Kaminski J, Dabrowski Z, Burdziakowska P. The stability of 5-aminolevulinic acid and its ester derivatives. Acta Pol Pharm. 2004;61:15–19
  28. Pearse AD. Applications for topical PDT: basal cell carcinomas. Photodyn News. 2002;5:1–5
  29. Sziemies RM, Sassy T, Landthaler M. Penetration potency of topical applied 5-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Photochem Photobiol. 1994;59:73–76
  30. Bretschko E, Szeimies RM, Landthaler M, Lee G. Topical 5-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Evaluation of stratum corneum permeability in vitro. J Control Release. 1996;42:203–208
  31. Moon SH, Foster MD. Influence of humidity on surface behaviour of pressure sensitive adhesives studied using scanning probe microscopy. Langmuir. 2002;18:8108–8115
  32. Lieb S, Szeimies RM, Lee G. Self-adhesive thin films for topical delivery of 5-aminolevulinic acid. Eur J Pharm Biopharm. 2002;53:99–106
  33. Pons P, Roald P, Nestor B, Rafael G, Agustin A. Transdermic patches for photodynamic therapy of superficial lesions. In: Proceedings of the 29th Annual Meeting of the American Society of Photobiology. Chicago, USA. 2001;
  34. McCarron PA, Donnelly RF, Gilmore BF, et al. Phototoxicity of 5-aminolevulinic acid in the HeLa cell line as an indicative measure of photodynamic effect after topical administration to gynaecological lesions of intraepithelial form. Pharm Res. 2004;21:1873–1881
  35. Manivasager V, Heng PWS, Hao J, Zheng W, Soom KC, Olivo M. Macro-microscopic fluorescence imaging of human NPC xenografts in a murine model using topical vs. intravenous administration of 5-aminolevulinic acid. Int J Oncol. 2002;21:1003–1007
  36. Manivasager V, Heng PWS, Hao J, Zheng W, Soom KC, Olivo M. A study of 5-aminolevulinic acid and its methyl ester used in in vitro and in vivo systems of human bladder cancer. Int J Oncol. 2003;22:313–318
  37. Uehlinger P, Zellweger M, Wagnieres G, Juillerat-Jeanneret L, Van den Bergh H, Lange N. 5-Aminolevulinic acid and it's derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J Photochem Photobiol B: Biol. 2000;54:72–80
  38. Williams AC. Transdermal and topical drug delivery. London: Pharmaceutical Press; 2003;
  39. Moan J, Ma LW, Iani V. On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters. Int J Cancer. 2001;92:139–143
  40. Moan J, Ma LW, Juzeniene A, et al. Pharmacology of protoporphyrin IX in nude mice after application of ALA and its esters. Int J Cancer. 2003;103:132–135

PII: S1572-1000(06)00056-1

doi: 10.1016/j.pdpdt.2006.03.007

Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 3 , Pages 190-201 , September 2006

Article Tools

* Image Usage & Resolution